ZYUS Life Sciences (TSE:ZYUS) has released an update.
ZYUS Life Sciences, a Canadian life sciences company, has secured a pivotal Cannabis Drug License from Health Canada, enabling the firm to manufacture cannabis-containing drugs for clinical trials. The license will facilitate the upcoming Phase 2 Clinical Trial of Trichomylin® softgel capsules for cancer-related pain management. Additionally, ZYUS strengthens its intellectual property portfolio with a new South African patent for another drug candidate, reflecting its commitment to innovating pain management solutions.
For further insights into TSE:ZYUS stock, check out TipRanks’ Stock Analysis page.
